CBER Tissue Products Office To Be Established By Oct. 1
This article was originally published in The Gray Sheet
Executive Summary
CBER's Office of Cells, Tissues & Gene Therapy will address the "evolution" of scientific and regulatory issues, FDA Center for Biologics Evaluation & Research Director Kathryn Zoon said May 29
You may also be interested in...
MDUFMA Addresses In Vitro Diagnostics, Combination Product Regulation
FDA will be required to report to Congress on Center for Biologics Evaluation & Research review times for in vitro diagnostics under the "Medical Device User Fee and Modernization Act" of 2002 (MDUFMA), which cleared the House Energy & Commerce Committee Oct. 2
MDUFMA Addresses In Vitro Diagnostics, Combination Product Regulation
FDA will be required to report to Congress on Center for Biologics Evaluation & Research review times for in vitro diagnostics under the "Medical Device User Fee and Modernization Act" of 2002 (MDUFMA), which cleared the House Energy & Commerce Committee Oct. 2
Potential Jurisdictional Change Draws Protest From Wound Product Firms
Wound healing products for which a primary mode of action cannot be elucidated should remain under the jurisdiction of FDA's device center, according to Apligraf manufacturer Organogenesis